Clinical Trial Update: Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial of intensified chemo-immuno-radiotherapy with durvalumab for Stage III non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Latin American Cooperative Oncology Group | Conditions: Lung Neoplasms | Phase 2 | Status: COMPLETED